Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309854 | PMC |
| http://dx.doi.org/10.2340/00015555-3705 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Rare Case of Congenital Buccal Lipoblastoma in a Term Neonate.
Cureus
December 2024
Pediatrics/Neonatology, University of Arkansas for Medical Sciences, Little Rock, USA.
A lipoblastoma is a benign tumor of adipocytes originating from embryonic white fat and occurs in the pediatric population. Congenital lipoblastomas, however, are rare, and the incidence of these tumors in neonates is unknown. Due to their rare presentation, congenital oral lipoblastomas can, firstly, pose diagnostic challenges for the pediatrician and must be differentiated from the more commonly seen oral lesions in the newborn and other rare malignant growths.
View Article and Find Full Text PDFFinite element investigation for improving chest wall reconstruction process using ceramic and polymeric implants.
Sci Rep
January 2025
Biomedical Engineering Department, Faculty of Engineering, Helwan University, Cairo, Egypt.
Car accidents, infections caused by bacteria or viruses, metastatic lesions, tumors, and malignancies are the most frequent causes of chest wall damage, leading to the removal of the affected area. After excision, artificial bone or synthetic materials are used in chest wall reconstruction to restore the skeletal structure of the chest. Chest implants have traditionally been made from metallic materials like titanium alloys due to their biocompatibility and durability.
View Article and Find Full Text PDFThe Effect of Denosumab on Pain and Radiological Improvement in Giant Cell Tumours of the Spine in the Acute Setting.
Global Spine J
January 2025
Department of Spinal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Study Design: Retrospective Cohort Study.
Objectives: The current recommended treatment for Giant Cell Tumour (GCT) of the spine is en bloc excision. Denosumab is a monoclonal antibody reducing osteoclast activity that shows promising results when used as a neo - adjuvant treatment.
Temozolomide treatment in refractory pituitary adenomas and pituitary carcinomas.
Neuroendocrinology
January 2025
Background: Temozolomide (TMZ), a non-classical alkylating agent, possesses lipophilic properties that allow it to cross the blood-brain barrier, making it active within the central nervous system. Furthermore, the adverse reactions of the TMZ are relatively mild, which is why it is currently recommended as a first-line chemotherapy drug for refractory pituitary adenomas (RPAs) and pituitary carcinomas (PCs).
Summary: Systematic evaluations indicate a radiological response rate of 41% and a hormonal response rate of 53%, underscoring TMZ clinical efficacy, particularly when combined with radiotherapy.
Bilateral Mediastinal Lymphadenectomy Is Associated With Potential Survival Advantages in Patients With Stage I Non-Small Cell Lung Cancer Who Undergo Lung Resection.
JCO Glob Oncol
January 2025
Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Purpose: The optimal lymphadenectomy approach for solid-dominant stage I non-small cell lung cancer (NSCLC) is controversial. We compared postlobectomy survival outcomes to elucidate.
Materials And Methods: Patients diagnosed with solid-dominant stage I NSCLC between 2008 and 2015 were included and grouped according to the mode of lymphadenectomy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!